{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:37:58Z","timestamp":1791549478344,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam UMC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lungcan.2024.107848","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T16:59:34Z","timestamp":1718211574000},"page":"107848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights"],"prefix":"10.1016","volume":"193","author":[{"given":"Aur\u00e9lie","family":"De Bruycker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Famke","family":"Schneiders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-4891","authenticated-orcid":false,"given":"Stephanie","family":"Gulstene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Moghanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-2204","authenticated-orcid":false,"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2024.107848_b0005","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2015.0071","article-title":"Non-small cell lung cancer, version 6.2015","volume":"13","author":"Ettinger","year":"2015","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"SUPPL.6","key":"10.1016\/j.lungcan.2024.107848_b0010","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Vansteenkiste","year":"2013","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2017.05.012","article-title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","volume":"124","author":"Guckenberger","year":"2017","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107848_b0020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0025","doi-asserted-by":"crossref","first-page":"e181390","DOI":"10.1001\/jamanetworkopen.2018.1390","article-title":"Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer","volume":"1","author":"Brooks","year":"2018","journal-title":"JAMA Netw Open."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/0284186X.2021.1874617","article-title":"Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK\u2019s largest cohort of lung SABR patients","volume":"60","author":"Saha","year":"2021","journal-title":"Acta Oncol. (Madr)"},{"key":"10.1016\/j.lungcan.2024.107848_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109697","article-title":"A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy","volume":"185","author":"Tonneau","year":"2023","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jtho.2019.10.016","article-title":"Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage NSCLC","volume":"15","author":"Brooks","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2016.12.022","article-title":"Stereotactic ablative radiation therapy is highly safe and effective for elderly patients with early-stage non-small cell lung cancer","volume":"98","author":"Brooks","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2024.107848_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110094","article-title":"Sub-lobar resections for peripheral non-small cell lung cancer measuring \u2264 2 cm: Insights from recent clinical trials","volume":"192","author":"Senan","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107848_b0055","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107848_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): Long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.radonc.2017.08.029","article-title":"Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy","volume":"125","author":"H\u00f6rner-Rieber","year":"2017","journal-title":"Radiother. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107848_b0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtho.2018.06.007","article-title":"Histology, tumor volume, and radiation dose predict outcomes in NSCLC patients after stereotactic ablative radiotherapy","volume":"13","author":"Shiue","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107848_b0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2018.12.022","article-title":"Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma","volume":"128","author":"Abel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107848_b0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2021.04.010","article-title":"Higher biologically effective dose is associated with improved survival in patients with squamous cell carcinoma of the lung treated with stereotactic body radiation therapy","volume":"160","author":"Parzen","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107848_b0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jamaoncol.2023.3495","article-title":"Individualized stereotactic ablative radiotherapy for lung tumors","volume":"9","author":"Gensheimer","year":"2023","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107848_b0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jtho.2016.11.002","article-title":"A histologic basis for the efficacy of SBRT to the lung","volume":"12","author":"Woody","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0095","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cllc.2022.11.005","article-title":"Trends in stage I lung cancer","volume":"24","author":"Singareddy","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0100","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.prro.2017.10.008","article-title":"Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an international Delphi consensus study","volume":"8","author":"Nguyen","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107848_b0105","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/annonc\/mdu089","article-title":"2nd ESMO Consensus Conference on Lung Cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up","volume":"25","author":"Vansteenkiste","year":"2014","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0110","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae insights: Non-small cell lung cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107848_b0115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JTO.0000000000000218","article-title":"A brief report on outcomes of stereotactic ablative radiotherapy for a second primary lung cancer: Evidence in support of routine CT surveillance","volume":"9","author":"Griffioen","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107848_b0120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non\u2013small-cell lung cancer","volume":"388","author":"Altorki","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10335","key":"10.1016\/j.lungcan.2024.107848_b0125","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.107848_b0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01306","article-title":"Secondary analysis of the rate of second primary lung cancer from cancer and Leukemia Group B 140503 (Alliance) trial of lobar versus sublobar resection for T1aN0 non\u2013small-cell lung cancer","author":"Stinchcombe","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107848_b0135","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0b013e318219aac5","article-title":"Radiological changes after stereotactic radiotherapy for stage I lung cancer","volume":"6","author":"Dahele","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107848_b0140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jtho.2018.02.023","article-title":"Brief Report on radiological changes following stereotactic ablative radiotherapy (SABR) for early-stage lung tumors: A pictorial essay","volume":"13","author":"Ronden","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107848_b0150","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107848_b0155","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"15","key":"10.1016\/j.lungcan.2024.107848_b0160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0165","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0170","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cllc.2016.08.002","volume":"18","author":"Swaminath","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107848_b0175","doi-asserted-by":"crossref","first-page":"dju164","DOI":"10.1093\/jnci\/dju164","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1\u20133 N0 M0 non-small cell lung cancer: NCIC CTG BR.25","volume":"106","author":"Cheung","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0180","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2024.107848_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109976","article-title":"What is the predictive value of RECIST criteria following stereotactic lung radiation?","volume":"190","author":"Gulstene","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2017.09.035","article-title":"Incidence of high-risk radiologic features in patients without local recurrence after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer","volume":"100","author":"Ronden","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2021.11.027","article-title":"A Systematic review into the radiologic features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC)","volume":"113","author":"Lee","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107848_b0200","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.radonc.2011.12.018","article-title":"Radiographic changes after lung stereotactic ablative radiotherapy (SABR) \u2013 Can we distinguish recurrence from fibrosis? A systematic review of the literature","volume":"102","author":"Huang","year":"2012","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.radonc.2013.06.047","article-title":"High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer","volume":"109","author":"Huang","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11604-009-0415-3","article-title":"Computed tomography appearances of local recurrence after stereotactic body radiation therapy for stage I non-small-cell lung carcinoma","volume":"28","author":"Kato","year":"2010","journal-title":"Jpn. J. Radiol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0215","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2007.07.2383","article-title":"Possible Misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer","volume":"70","author":"Takeda","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107848_b0220","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10147-007-0691-9","article-title":"Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors","volume":"12","author":"Matsuo","year":"2007","journal-title":"Int. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107848_b0225","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Seminars Ultrasound CT MRI"},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0230","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1378\/chest.13-2281","article-title":"Assessing the usefulness of 18 F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer","volume":"146","author":"Pastis","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0235","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/j.ijrobp.2012.01.012","article-title":"Residual 18F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control","volume":"83","author":"Bollineni","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.lungcan.2024.107848_b0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12149-012-0682-4","article-title":"Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: Characterization of 18F-FDG PET\/CT findings","volume":"27","author":"Nakajima","year":"2013","journal-title":"Ann. Nucl. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0245","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"10.1016\/j.lungcan.2024.107848_b0250","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","article-title":"Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: A systematic review","volume":"98","author":"Chen","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0255","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ijrobp.2023.06.289","article-title":"Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): Primary analysis of a phase II trial","volume":"117","author":"Palma","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2024.107848_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.01.217","article-title":"Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: A systematic review and meta-analysis","author":"Han","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10405","key":"10.1016\/j.lungcan.2024.107848_b0265","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0270","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijrobp.2023.03.069","article-title":"Safety and efficacy results from iSABR, a phase 1 study of stereotactic ABlative radiotherapy in combination with durvalumab for early-stage medically inoperable non-small cell lung cancer","volume":"117","author":"Wu","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0275","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijrobp.2019.12.030","article-title":"Lung stereotactic body radiation therapy and concurrent immunotherapy: A multicenter safety and toxicity analysis","volume":"108","author":"Tian","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.lungcan.2024.107848_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110147","article-title":"Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer","volume":"194","author":"Smesseim","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107848_b0285","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.athoracsur.2013.07.123","article-title":"Salvage operation for late recurrence after stereotactic body radiotherapy for lung cancer: Two patients with no viable cancer cells","volume":"97","author":"Taira","year":"2014","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2024.107848_b0290","article-title":"Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review","volume":"10","author":"Dickhoff","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107848_b0295","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41598-024-52828-4","article-title":"Distinguishing recurrence from radiation-induced lung injury at the time of RECIST progressive disease on post-SABR CT scans using radiomics","volume":"14","author":"Dammak","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107848_b0300","doi-asserted-by":"crossref","first-page":"e60279","DOI":"10.1371\/journal.pone.0060279","article-title":"Differentiation of central lung cancer from atelectasis: Comparison of diffusion-weighted MRI with PET\/CT","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107848_b0305","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clon.2019.05.014","article-title":"A prospective study of magnetic resonance imaging assessment of post-radiation changes following stereotactic body radiation therapy for non-small cell lung cancer","volume":"31","author":"Munoz-Schuffenegger","year":"2019","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107848_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107265","article-title":"Magnetic resonance imaging for prospective assessment of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy","volume":"182","author":"Kirshenboim","year":"2023","journal-title":"Lung Cancer"},{"issue":"6_suppl","key":"10.1016\/j.lungcan.2024.107848_b0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107848_b0320","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"issue":"29","key":"10.1016\/j.lungcan.2024.107848_b0325","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.lungcan.2024.107848_b0330","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107848_b0335","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/jso.27404","article-title":"Salvage surgery for local recurrences after stereotactic ablative radiotherapy of colorectal pulmonary metastases","volume":"128","author":"van Dorp","year":"2023","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2024.107848_b0340","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2021.10.023","article-title":"A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study","volume":"166","author":"Nicosia","year":"2022","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2024.107848_b0345","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2023.11.008","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer","volume":"35","author":"Tran","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107848_b0355","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.cllc.2023.11.013","article-title":"Detection of circulating tumor DNA after stereotactic ablative radiotherapy in patients with unbiopsied lung tumors (SABR-DETECT)","volume":"25","author":"Verma","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2024.107848_b0360","article-title":"Evaluation of post-lung SABR imaging: A proposed pathway","volume":"192","author":"De Bruycker","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2024.107848_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110080","article-title":"Response to evaluation of post-lung SABR imaging: A proposed pathway","volume":"192","author":"Gulstene","year":"2024","journal-title":"Radiother. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T05:35:51Z","timestamp":1727242551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224003829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":73,"alternative-id":["S0169500224003829"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107848","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107848"}}